Germany-based MorphoSys and Belgian firm Galapagos have announced that dosing of human monoclonal antibody MOR106 in healthy volunteers has started in a Phase 1 study.

MOR106 was jointly discovered by MorphoSys and Galapagos and has a new mode of action with potential application in inflammation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The main objective in the randomised, double-blind, placebo-controlled study conducted in a single centre in Belgium is to assess the safety and tolerability of single doses of MOR106.

The study includes around 56 healthy volunteers and evaluates single ascending doses (SAD) administered as intravenous infusion.

"MOR106 is MorphoSys’s fifth proprietary antibody programme in clinical development and the first from our novel Ylanthia technology platform."

The Phase 1 study is also characterised by its adaptive design, which allows the initiation of a subsequent multiple ascending dose (MAD) study in patients, depending on the outcome of the SAD study in healthy volunteers.

See Also:

Secondary objective of the study is to characterise the pharmacokinetic profile of MOR106 and observe the occurrence of anti-drug antibodies as a measure of immunogenicity with MOR106.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Results of the complete study, including the potential subsequent MAD part in patients, are expected to come in the second half of next year.

MorphoSys chief development officer Arndt Schottelius said: "MOR106 is MorphoSys’s fifth proprietary antibody programme in clinical development and the first from our novel Ylanthia technology platform.

"We are excited about the growing value and maturity of our development pipeline.

"The start of this very innovative clinical development programme also reflects the high value of our ongoing collaboration with Galapagos."

MorphoSys noted that while developing MOR106, it provided its Ylanthia antibody technology to generate fully human antibodies directed against the target and Galapagos provided the disease-related biology such as cellular assays.

Both Galapagos and MorphoSys expect to continue to equally share the research and development costs of MOR106, and all future revenues.